- Home
- YALA vs OBX Comparison
YALA vs OBX Comparison
Compare YALA & OBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YALA | OBX |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | United Arab Emirates | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 844.2M | 861.1M |
| IPO Year | 2020 | 2026 |
Fundamental Metrics
Financial Performance| Metric | YALA | OBX |
|---|---|---|
| Price | $5.60 | $14.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $7.28 | ★ $39.00 |
| AVG Volume (30 Days) | 311.3K | ★ 319.6K |
| Earning Date | 11-09-2026 | 11-13-2026 |
| Dividend Yield | ★ 4.97% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $0.00 | N/A |
| Revenue Next Year | $12.03 | N/A |
| P/E Ratio | $8.76 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.01 | $11.52 |
| 52 Week High | $7.83 | $39.00 |
Technical Indicators
Market Signals| Indicator | YALA | OBX |
|---|---|---|
| Relative Strength Index (RSI) | 54.56 | 47.58 |
| Support Level | $5.22 | $11.84 |
| Resistance Level | $5.66 | $14.60 |
| Average True Range (ATR) | 0.09 | 1.05 |
| MACD | 0.01 | 0.42 |
| Stochastic Oscillator | 69.86 | 79.22 |
Price Performance
Historical ComparisonAbout YALA Yalla Group Limited each representing one
Yalla Group Ltd is a MENA-based online social networking and gaming company. It operates two flagship mobile applications, Yalla, a voice-centric group chat platform, and Yalla Ludo, a casual gaming application featuring online versions of board games popular in MENA, with in-game voice chat and localized majlis functions. The group has one operating segment, which is the social networking and entertainment platform.
About OBX Obsidian Therapeutics Inc. Common Stock
Obsidian Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor infiltrating lymphocytes (TIL) cell therapies for the treatment of patients with solid tumors. The company's proprietary cytoDRiVE platform is versatile and allows it to leverage drug responsive domains to control protein function, with its initial focus on TIL cell therapies developed from this platform (cytoTILs). The company's flagship product candidate, OBX-115, is a novel, genetically engineered, autologous TIL cell therapy currently in a Phase 2 clinical trial for the treatment of melanoma and a Phase 1 clinical trial for the treatment of non-small cell lung cancer.